A Population-based Prospective Study of Metastatic Colorectal Cancer (CRC) Patients in Finland

Conditions

Metastatic Colorectal Cancer

Keywords

metastatic colorectal cancer

Brief summary

* A population-based prospective study to evaluate clinical behaviour, resectability and survival in 1st line metastatic colorectal cancer (CRC) patients in Finland * Primary objective: To assess clinical behaviour of metastatic colorectal cancer and overall resectability, postoperative morbidity and outcomes after resection * Secondary objectives: To assess treatments for mCRC; To assess efficacy of chemotherapy and targeted drugs with overall response rates (ORR), failure free survival (FFS), progression free survival (PFS), and overall survival (OS); To radiologically assess tumour density and morphology, and assess alternative radiologic response evaluation in comparison with RECIST response criteria; To evaluate whole blood, plasma, serum and tumour block biomarkers and DNA polymorphisms that may predict drug effects, resectability and clinical behaviour of the tumour

Pia Österlund, Joel Kontiainen, Kaisa Lehtomäki, Timo Muhonen, Aki Uutela et al. (20 authors)

Journal of Clinical Oncology2025-05-281 citations

10.1200/jco.2025.43.16_suppl.3566

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study

Aki Uutela, Emerik Österlund, Päivi Halonen, Raija Kallio, Annika Ålgars et al. (25 authors)

British Journal of Cancer2022-05-2416 citations

10.1038/s41416-022-01858-8

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study.

Osterlund P, Kinos S, Pfeiffer P, Salminen T, Kwakman JJM, Frödin JE, Shah CH, Sorbye H, Ristamäki R, Halonen P, Soveri LM, Heervä E, Ålgars A, Bärlund M, Hagman H, McDermott R, O'Reilly M, Röckert R, Liposits G, Kallio R, Flygare P, Teske AJ, van Werkhoven E, Punt CJA, Glimelius B.

2022-03-3019 citations

10.1016/j.esmoop.2022.100427

Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and 1H-MR spectroscopy compared with histology (subgroup in the RAXO trial).

Uutela A, Ovissi A, Hakkarainen A, Ristimäki A, Lundbom N, Kallio R, Soveri LM, Salminen T, Ålgars A, Halonen P, Ristamäki R, Nordin A, Blanco Sequeiros R, Rinta-Kiikka I, Lantto E, Virtanen J, Pääkkö E, Liukkonen E, Saunavaara J, Ryymin P, Lammentausta E, Osterlund P, Isoniemi H, RAXO Study Group.

2021-07-2611 citations

10.1016/j.esmoop.2021.100208

Resectability, conversion and resections rates, and outcomes in RAS&BRAF wildtype (wt), RAS mutant (mt) and BRAFmt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study.

Pia Österlund, Emerik Österlund, Aki Uutela, Päivi Halonen, Raija S. Kallio et al. (21 authors)

Journal of Clinical Oncology2021-05-202 citations

10.1200/jco.2021.39.15_suppl.3532

Repeated centralized MDT resectability assessment during first-line treatment in 1086 Finnish metastatic colorectal cancer (mCRC) patients nationwide (prospective RAXO study).

Pia Österlund, Raija S. Kallio, Ilmo Kellokumpu, Leena‐Maija Soveri, Annika Ålgars et al. (21 authors)

Journal of Clinical Oncology2019-05-20

10.1200/jco.2019.37.15_suppl.3517

Interventions

OTHERBiomarker sampling

Blood samples every 8-12 weeks

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

1. Patients with histologically confirmed CRC, who are scheduled to start or are getting first line chemotherapy for metastatic disease 2. Age \> 18 3. Metastatic disease (including locally advanced disease not amenable with surgery and/or (chemo)radiotherapy) 4. Signed written informed consent according to ICH/GCP and the local regulations (approved by the Independent Ethics Committee \[IEC\]) will be obtained prior to study 5. No informed consent will be obtained from patients participating in the data collection study obtaining data from hospital charts. No blood sampling, nor contacting of patients will be performed.

Design outcomes

Primary

Measure	Time frame	Description
Resectability	5 years	To assess clinical behaviour of metastatic colorectal cancer and overall resectability, postoperative morbidity and outcomes after resection

Secondary

Measure	Time frame	Description
Radiological assessment	5 years	To radiologically assess tumour density and morphology, and assess alternative radiologic response evaluation in comparison with RECIST response criteria
Efficacy	5 years	Response rates
Safety	5 years	Number of adverse events

Countries

Finland

Contacts

Primary ContactPia Osterlund, MD

pia.osterlund@hus.fi+358-9-4711

Outcome results

None listed